Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

BOSTON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity Fund) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or v...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

SAN JOSE, Calif.--(BUSINESS WIRE)--Emery Unified School District sued for allegedly failing to protect students from former coach/security guard accused of assaults....

BELLEVUE, Wash.--(BUSINESS WIRE)--As hundreds of thousands of fans arrive in the Bay Area for Sunday’s Big Game, T-Mobile (NASDAQ: TMUS), home of America’s Best Network, has engineering and support teams positioned on the ground in critical locations across the Bay Area to deliver the network speed, reliability and capacity first responders and public safety officials rely on. The Big Game and similar events place unique demands on communications and coordination and network performance. Well i...

BELLEVUE, Wash.--(BUSINESS WIRE)--A medida que miles de fans llegan a la Bay Area para el Gran Partido del domingo, T-Mobile (NASDAQ: TMUS), hogar de la Mejor Red del País, cuenta con equipos de ingeniería y asistencia ubicados en lugares clave para ofrecer la velocidad, confiabilidad y capacidad de la red en la que confían el personal de emergencia y los funcionarios de seguridad pública. El Gran Juego y eventos similares impone requisitos específicos de las comunicaciones, la coordinación y e...

ウィスコンシン州マディソン--(BUSINESS WIRE)--（ビジネスワイヤ） -- 中国国家薬品監督管理局（NMPA）は、中国において、OncoMate® マイクロサテライト不安定性（MSI）検出キットを第III類の体外診断用医療機器として承認しました。本製品は、メルク・アンド・カンパニー（米国ニュージャージー州ローウェイ）の抗PD-1抗体療法であるKEYTRUDA®（ペムブロリズマブ）治療の対象となる、MSI-High（MSI-H）の固形がん患者を特定するためのコンパニオン診断薬としての使用を目的としています。また、プロメガのコンパニオン診断薬として初めてNMPAの承認を取得しました。 「今回の承認は、中国における、より個別化された効果的ながん治療の実現に向けた一歩となります」と、プロメガのグローバル臨床マーケット・ディレクターであるアロク・シャルマは述べています。「当社は、革新的な技術や人命を救う効果的な治療法へのアクセス拡大につながる世界的なソリューションを提供するために、製薬企業と協業できることを誇りに思います。」 中国では、依然として世界でも特に高いがん負担に直面して...

MADISON, Wisconsin, USA--(BUSINESS WIRE)--Chinas nationale Aufsichtsbehörde für Medizinprodukte, NMPA (National Medical Products Administration), hat das OncoMate® -Kit zum Nachweis von Mikrosatelliteninstabilität (MSI) als In-vitro-Diagnostikum der Klasse III in China zugelassen. Das Kit soll als Begleitdiagnostikum zur Identifizierung von hochgradiger Mikrosatelliteninstabilität (MSI-H) bei Patienten mit soliden Tumoren für die Behandlung mit KEYTRUDA® (Pembrolizumab) dienen, einer Anti-PD-1-...